Topics

US failure to adopt biosimilars costs $7.2bn every year

10:49 EDT 12 Jul 2019 | BioPharma-Reporter

With US spending on biologics reaching $125.5bn in 2018, a new report looks at the level of savings that could potentially be made and contrasts the US with the European market.

Original Article: US failure to adopt biosimilars costs $7.2bn every year

NEXT ARTICLE

More From BioPortfolio on "US failure to adopt biosimilars costs $7.2bn every year"

Quick Search

Relevant Topic

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...